Outcome of liver transplantation in hepatitis C virus-infected patients who received hepatitis C virus-infected grafts.

PubWeight™: 2.19‹?› | Rank: Top 2%

🔗 View Article (PMID 10381921)

Published in Gastroenterology on July 01, 1999

Authors

H E Vargas1, T Laskus, L F Wang, R Lee, M Radkowski, F Dodson, J J Fung, J Rakela

Author Affiliations

1: Division of Gastroenterology and Hepatology, T. E. Starzl Transplantation Institute, University of Pittsburgh, Pittsburgh, Pennsylvania, USA. hvargas@pitt.edu

Articles citing this

Survival after liver transplantation using hepatitis C virus-positive donor allografts: case-controlled analysis of the UNOS database. World J Surg (2011) 1.57

Compartmentalization of hepatitis C virus genotypes between plasma and peripheral blood mononuclear cells. J Virol (2005) 1.41

PHS guideline for reducing human immunodeficiency virus, hepatitis B virus, and hepatitis C virus transmission through organ transplantation. Public Health Rep (2013) 1.17

Exposure of hepatitis C virus (HCV) RNA-positive recipients to HCV RNA-positive blood donors results in rapid predominance of a single donor strain and exclusion and/or suppression of the recipient strain. J Virol (2001) 1.12

Use of extended criteria livers decreases wait time for liver transplantation without adversely impacting posttransplant survival. Ann Surg (2006) 1.06

Post-liver transplant hepatitis C virus recurrence: an unresolved thorny problem. World J Gastroenterol (2014) 0.83

Utilization of hepatitis C antibody-positive livers: genotype dominance is virally determined. Transpl Int (2012) 0.80

Human liver transplantation as a model to study hepatitis C virus pathogenesis. Liver Transpl (2009) 0.79

Use of hepatitis C-infected donors for hepatitis C-positive OLT recipients. Gastroenterology (1999) 0.78

Will transplantation of an hepatitis C-infected graft improve the outcome of liver transplantation in HCV patients? Gastroenterology (1999) 0.75

Long term follow-up and outcome of liver transplantation from hepatitis B surface antigen positive donors. World J Gastroenterol (2017) 0.75

Articles by these authors

Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell (1997) 15.96

Cell migration and chimerism after whole-organ transplantation: the basis of graft acceptance. Hepatology (1993) 8.76

The many faces of multivisceral transplantation. Surg Gynecol Obstet (1991) 6.89

Effect of antioxidants on the occurrence of pre-eclampsia in women at increased risk: a randomised trial. Lancet (1999) 6.69

Mycolactone: a polyketide toxin from Mycobacterium ulcerans required for virulence. Science (1999) 6.37

Guided medication dosing for inpatients with renal insufficiency. JAMA (2001) 6.25

Bone marrow augmentation of donor-cell chimerism in kidney, liver, heart, and pancreas islet transplantation. Lancet (1994) 5.54

Liver, kidney, and thoracic organ transplantation under FK 506. Ann Surg (1990) 5.01

Intestinal transplantation in composite visceral grafts or alone. Ann Surg (1992) 4.96

Murine liver allograft transplantation: tolerance and donor cell chimerism. Hepatology (1994) 4.32

Pancreatic islet transplantation after upper abdominal exenteration and liver replacement. Lancet (1990) 4.18

Facial fractures and submental tracheal intubation. Anaesthesia (2002) 4.13

The Australian Incident Monitoring Study. Crisis management--validation of an algorithm by analysis of 2000 incident reports. Anaesth Intensive Care (1993) 4.04

A 21-year experience with major hemorrhage after percutaneous liver biopsy. Gastroenterology (1990) 4.02

Liver transplantation in the United States, 1999-2008. Am J Transplant (2010) 3.92

Variable chimerism, graft-versus-host disease, and tolerance after different kinds of cell and whole organ transplantation from Lewis to brown Norway rats. Transplantation (1995) 3.63

An STS-based radiation hybrid map of the human genome. Genome Res (1997) 3.57

Selected topics on FK 506, with special references to rescue of extrahepatic whole organ grafts, transplantation of "forbidden organs," side effects, mechanisms, and practical pharmacokinetics. Transplant Proc (1991) 3.40

Hepatitis C virus genotypes in the United States: epidemiology, pathogenicity, and response to interferon therapy. Collaborative Study Group. Ann Intern Med (1996) 3.38

Orthotopic liver transplantation for patients with hepatitis B virus-related liver disease. Hepatology (1991) 3.34

Early trials with FK 506 as primary treatment in liver transplantation. Transplant Proc (1990) 3.29

A strong sequence homology exists between the major RNA polymerase sigma factors of Bacillus subtilis and Escherichia coli. J Biol Chem (1985) 3.28

Use of OKT3 with cyclosporin and steroids for reversal of acute kidney and liver allograft rejection. Nephron (1987) 3.26

Multiple procaryotic ribonucleic acid polymerase sigma factors. Microbiol Rev (1986) 3.25

Rejection of multivisceral allografts in rats: a sequential analysis with comparison to isolated orthotopic small-bowel and liver grafts. Surgery (1990) 3.18

The effect of graft function on FK506 plasma levels, dosages, and renal function, with particular reference to the liver. Transplantation (1991) 3.14

Long-term survival after liver transplantation in 4,000 consecutive patients at a single center. Ann Surg (2000) 2.91

Emerging viral diseases of Southeast Asia and the Western Pacific. Emerg Infect Dis (2001) 2.91

Functional characterization of infiltrating T lymphocytes in human hepatic allografts. Hum Immunol (1986) 2.84

Effect of RF coil excitation on field inhomogeneity at ultra high fields: a field optimized TEM resonator. Magn Reson Imaging (2001) 2.84

Hematolymphoid cell trafficking, microchimerism, and GVH reactions after liver, bone marrow, and heart transplantation. Transplant Proc (1993) 2.81

Prospective evaluation of a matrix-assisted laser desorption ionization-time of flight mass spectrometry system in a hospital clinical microbiology laboratory for identification of bacteria and yeasts: a bench-by-bench study for assessing the impact on time to identification and cost-effectiveness. J Clin Microbiol (2012) 2.80

Cadaveric small bowel and small bowel-liver transplantation in humans. Transplantation (1992) 2.75

Variable and tissue-specific hormone resistance in heterotrimeric Gs protein alpha-subunit (Gsalpha) knockout mice is due to tissue-specific imprinting of the gsalpha gene. Proc Natl Acad Sci U S A (1998) 2.71

A case series of transplant recipients who despite immunosuppression developed inflammatory bowel disease. Am J Gastroenterol (1997) 2.65

Management of intestinal transplantation in humans. Transplant Proc (1992) 2.62

Effect of hepatic dysfunction and T tube clamping on FK 506 pharmacokinetics and trough concentrations. Transplant Proc (1990) 2.60

Suppression of allograft rejection with FK506. I. Prolonged cardiac and liver survival in rats following short-course therapy. Transplantation (1990) 2.59

Incidence and treatment of rejection episodes in primary orthotopic liver transplantation under FK 506. Transplant Proc (1991) 2.59

The prediction of risk of recurrence and time to recurrence of hepatocellular carcinoma after orthotopic liver transplantation: a pilot study. Hepatology (1997) 2.57

FK506 "rescue" for resistant rejection of renal allografts under primary cyclosporine immunosuppression. Transplantation (1994) 2.50

Pregnancy after liver transplantation under tacrolimus. Transplantation (1997) 2.50

Pharmacokinetics of FK 506: preclinical and clinical studies. Transplant Proc (1990) 2.48

Prioritization and organ distribution for liver transplantation. JAMA (1994) 2.38

Helios, a T cell-restricted Ikaros family member that quantitatively associates with Ikaros at centromeric heterochromatin. Genes Dev (1998) 2.37

The antibody crossmatch in liver transplantation. Surgery (1986) 2.33

The mouse c-abl locus: molecular cloning and characterization. Cell (1984) 2.33

The incidence, timing, and management of biliary tract complications after orthotopic liver transplantation. Ann Surg (1994) 2.32

Clinical intestinal transplantation: new perspectives and immunologic considerations. J Am Coll Surg (1998) 2.31

Differential survival of hamster-to-rat liver and cardiac xenografts under FK 506 immunosuppression. Transplant Proc (1991) 2.28

Assessment of five-year experience with abdominal organ cluster transplantation. J Am Coll Surg (1995) 2.25

Should HLA mismatch acceptability for sensitized transplant candidates be determined at the high-resolution rather than the antigen level? Am J Transplant (2015) 2.24

Hepatic resection for metastatic colorectal adenocarcinoma: a proposal of a prognostic scoring system. J Am Coll Surg (1999) 2.22

Immunosuppression: evolution in practice and trends, 1994-2004. Am J Transplant (2006) 2.22

Adductor tenotomies in children with quadriplegic cerebral palsy: longer term follow-up. J Pediatr Orthop (2000) 2.21

Human islet isolation and allotransplantation in 22 consecutive cases. Transplantation (1992) 2.20

Three years clinical experience with intestinal transplantation. J Am Coll Surg (1994) 2.20

The nature of unexplained chronic aminotransferase elevations of a mild to moderate degree in asymptomatic patients. Hepatology (1989) 2.19

Mice lacking major histocompatibility complex class I and class II molecules. Proc Natl Acad Sci U S A (1993) 2.18

Intensive cataract training: a novel approach. Eye (Lond) (2013) 2.17

N-cadherin regulates target specificity in the Drosophila visual system. Neuron (2001) 2.16

Minimal criteria for placement of adults on the liver transplant waiting list: a report of a national conference organized by the American Society of Transplant Physicians and the American Association for the Study of Liver Diseases. Liver Transpl Surg (1997) 2.16

Differences in outcomes for patients with bacteremia due to vancomycin-resistant Enterococcus faecium or vancomycin-susceptible E. faecium. Clin Infect Dis (1996) 2.12

Modification and validation of the Birmingham Vasculitis Activity Score (version 3). Ann Rheum Dis (2008) 2.12

One hundred ten consecutive primary orthotopic liver transplants under FK 506 in adults. Transplant Proc (1991) 2.10

A prospective randomized trial of FK506-based immunosuppression after renal transplantation. Transplantation (1995) 2.09

The side effects of FK 506 in humans. Transplant Proc (1990) 2.08

Randomised trialomania? The multicentre liver transplant trials of tacrolimus. Lancet (1995) 2.04

In vivo cytokine gene expression in T cell subsets of the autoimmune MRL/Mp-lpr/lpr mouse. Eur J Immunol (1990) 2.00

Treatment of hilar cholangiocarcinoma (Klatskin tumors) with hepatic resection or transplantation. J Am Coll Surg (1998) 1.99

Access to data: comparing AccessMed with Query by Review. J Am Med Inform Assoc (1996) 1.98

Secreted proNGF is a pathophysiological death-inducing ligand after adult CNS injury. Proc Natl Acad Sci U S A (2004) 1.98

Central nervous system toxicity after liver transplantation. The role of cyclosporine and cholesterol. N Engl J Med (1987) 1.98

Prevention of graft-versus-host disease following allogeneic bone marrow transplantation in rats using FK506. Transplantation (1991) 1.95

FK 506 in steroid-resistant focal sclerosing glomerulonephritis of childhood. Lancet (1990) 1.94

Successful hamster-to-rat liver xenotransplantation under FK506 immunosuppression induces unresponsiveness to hamster heart and skin. Transplantation (1993) 1.94

Acute liver failure: clinical features, outcome analysis, and applicability of prognostic criteria. Liver Transpl (2000) 1.88

Growth of donor-derived dendritic cells from the bone marrow of murine liver allograft recipients in response to granulocyte/macrophage colony-stimulating factor. J Exp Med (1995) 1.88

The role of "indirect" recognition in initiating rejection of skin grafts from major histocompatibility complex class II-deficient mice. Proc Natl Acad Sci U S A (1993) 1.86

Costimulatory molecule-deficient dendritic cell progenitors (MHC class II+, CD80dim, CD86-) prolong cardiac allograft survival in nonimmunosuppressed recipients. Transplantation (1996) 1.86

Nucleotide sequence and organization of Bacillus subtilis RNA polymerase major sigma (sigma 43) operon. Nucleic Acids Res (1986) 1.86

Experience with liver and kidney allografts from non-heart-beating donors. Transplantation (1995) 1.83

Orthotopic liver transplantation in the mouse. Transplantation (1991) 1.82

Apoptosis within spontaneously accepted mouse liver allografts: evidence for deletion of cytotoxic T cells and implications for tolerance induction. J Immunol (1997) 1.81

Pathologic observations in human allograft recipients treated with FK 506. Transplant Proc (1990) 1.80

Early events in liver allograft rejection. Delineation of sites of simultaneous intragraft and recipient lymphoid tissue sensitization. Am J Pathol (1991) 1.78

Inhibition of cyclooxygenase-2 suppresses angiogenesis and the growth of prostate cancer in vivo. J Urol (2000) 1.78

Use of FK 506 in pediatric patients. Transplant Proc (1991) 1.77

Cloning and expression of a smooth muscle caldesmon. J Biol Chem (1989) 1.74

Angiopoietin-1 is expressed in the synovium of patients with rheumatoid arthritis and is induced by tumour necrosis factor alpha. Ann Rheum Dis (2003) 1.74

Diagnosis and management of rhinitis: complete guidelines of the Joint Task Force on Practice Parameters in Allergy, Asthma and Immunology. American Academy of Allergy, Asthma, and Immunology. Ann Allergy Asthma Immunol (1998) 1.73

Randomized trial of FK 506/prednisone vs FK 506/azathioprine/prednisone after renal transplantation: preliminary report. Transplant Proc (1993) 1.72

Transplantation. JAMA (1990) 1.71

Expression of cyclooxygenase-1 and cyclooxygenase-2 in the human prostate. Urology (2000) 1.71